These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
193 related items for PubMed ID: 15661417
1. Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. Rosano GM, Aversa A, Vitale C, Fabbri A, Fini M, Spera G. Eur Urol; 2005 Feb; 47(2):214-20; discussion 220-2. PubMed ID: 15661417 [Abstract] [Full Text] [Related]
2. Relationship between chronic tadalafil administration and improvement of endothelial function in men with erectile dysfunction: a pilot study. Aversa A, Greco E, Bruzziches R, Pili M, Rosano G, Spera G. Int J Impot Res; 2007 Feb; 19(2):200-7. PubMed ID: 16943794 [Abstract] [Full Text] [Related]
5. Circulating endothelial progenitor cells and endothelial function after chronic Tadalafil treatment in subjects with erectile dysfunction. Foresta C, Ferlin A, De Toni L, Lana A, Vinanzi C, Galan A, Caretta N. Int J Impot Res; 2006 Feb; 18(5):484-8. PubMed ID: 16541115 [Abstract] [Full Text] [Related]
7. Factors associated with preference for sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy: post hoc analysis of data from a multicentre, randomized, open-label, crossover study. Eardley I, Montorsi F, Jackson G, Mirone V, Chan ML, Loughney K, Vail GM, Beardsworth A. BJU Int; 2007 Jul; 100(1):122-9. PubMed ID: 17552960 [Abstract] [Full Text] [Related]
12. Erectile dysfunction in systemic sclerosis: effects of longterm inhibition of phosphodiesterase type-5 on erectile function and plasma endothelin-1 levels. Proietti M, Aversa A, Letizia C, Rossi C, Menghi G, Bruzziches R, Merla A, Spera G, Salsano F. J Rheumatol; 2007 Aug; 34(8):1712-7. PubMed ID: 17611982 [Abstract] [Full Text] [Related]
13. In patients with coronary artery disease endothelial function is associated with plasma levels of C-reactive protein and is improved by optimal medical therapy. Vitale C, Cerquetani E, Wajngarten M, Leonardo F, Silvestri A, Mercuro G, Fini M, Ramires JA, Rosano GM. Ital Heart J; 2003 Sep; 4(9):627-32. PubMed ID: 14635381 [Abstract] [Full Text] [Related]
17. Efficacy, safety, and treatment satisfaction of tadalafil versus placebo in patients with erectile dysfunction evaluated at tertiary-care academic centers. Carson C, Shabsigh R, Segal S, Murphy A, Fredlund P, Kuepfer C, Trial Evaluating the Activity of Tadalafil for Erectile Dysfunction-United States (TREATED-US) Study Group. Urology; 2005 Feb; 65(2):353-9. PubMed ID: 15708052 [Abstract] [Full Text] [Related]
18. Tadalafil improved erectile function at twenty-four and thirty-six hours after dosing in men with erectile dysfunction: US trial. Young JM, Feldman RA, Auerbach SM, Kaufman JM, Garcia CS, Shen W, Murphy AM, Beasley CM, Hague JA, Ahuja S. J Androl; 2005 Feb; 26(3):310-8. PubMed ID: 15866997 [Abstract] [Full Text] [Related]
20. Sildenafil citrate for erectile dysfunction in men with diabetes and cardiovascular risk factors: a retrospective analysis of pooled data from placebo-controlled trials. Blonde L. Curr Med Res Opin; 2006 Nov; 22(11):2111-20. PubMed ID: 17076971 [Abstract] [Full Text] [Related] Page: [Next] [New Search]